AIP
VRTX icon

Arrowpoint Investment Partners’s Vertex Pharmaceuticals VRTX Stock Holding History

Arrowpoint Investment Partners’s Portfolio VRTX Stock Details VRTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q2 		– Sell
-1,600
Closed -$776K – 854
2025
Q1 		$776K Sell
1,600
-3,000
-65% -$1.4M 0.09% 256
2024
Q4 		$1.85M Buy
+4,600
New +$2.13M 0.38% 56

Other funds holding VRTX

Capital World Investors
Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
Capital International Investors
Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return

Arrowpoint Investment Partners's VRTX Position: Q1 2026 in Review

Arrowpoint Investment Partners increased its Vertex Pharmaceuticals (VRTX) stake by 1.4% in Q1 2026, buying an estimated $22.4K and bringing the position to 3,412 shares worth $1.52M. The position accounts for 1.35% of the portfolio, ranked #18.

Arrowpoint Investment Partners first reported a position in VRTX in Q1 2025 and has held it in 3 quarters since. The position peaked at $1.53M in Q4 2025. 1,691 funds tracked by Wall St. Rank hold VRTX as of Q1 2026.

  • Arrowpoint Investment Partners held 3,412 shares of Vertex Pharmaceuticals worth $1.52M as of Q1 2026.
  • Arrowpoint Investment Partners bought 48 Vertex Pharmaceuticals shares in Q1 2026, an estimated $22.4K.
  • Vertex Pharmaceuticals made up 1.35% of Arrowpoint Investment Partners's portfolio in Q1 2026, its #18 holding.
  • Arrowpoint Investment Partners first reported a position in Vertex Pharmaceuticals in Q1 2025 and has held it in 3 quarters since.
  • Arrowpoint Investment Partners's Vertex Pharmaceuticals position peaked at $1.53M in Q4 2025.
  • 1,691 funds tracked by Wall St. Rank held Vertex Pharmaceuticals as of Q1 2026.

Based on Arrowpoint Investment Partners's 13F filing for Q1 2026, filed 14 May 2026.